Home › Compare › DKLRF vs ABBV
DKLRF yields 181818.18% · ABBV yields 3.06%● Live data
📍 DKLRF pulled ahead of the other in Year 1
Combined, DKLRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DKLRF + ABBV for your $10,000?
Decklar Resources Inc. operates as an independent international oil and gas company in Nigeria and Canada. The company explores for copper, lead, and zinc deposits. It focuses on appraisal and development in the West African region. The company holds interests in the Oza Oil Field that covers an area of 20 square kilometers located onshore in the northern part of Oil Mining Lease (OML) 11 in Nigeria's Eastern Niger Delta; the Asaramatoru Field located onshore in the southern swamp section of OML 11 in the Eastern Niger Delta; and the Emohua Oil Field located onshore in the southeastern section of OML 22 in the Eastern Niger Delta. It also holds an option to acquire a 75% interest in the Holt property that covers an area of 3,687 hectares located in east of Duncan, British Columbia. It also provides funding and technical advisory services to exploration and development companies The company was formerly known as Asian Mineral Resources Limited and changed its name to Decklar Resources Inc. in September 2020. Decklar Resources Inc. was incorporated in 2004 and is based in Toronto, Canada.
Full DKLRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.